Efficacy of Vericiguat in Acute Heart Failure: A Target Trial Emulation Study - PubMed

5 hours ago

Vericiguat reduced 180-day HF rehospitalization from 34.2% to 16.3% in acute HF patients.
Worsening HF events were numerically lower in the vericiguat group (21.2% vs. 31.1%).
Patients on vericiguat showed significant improvement in New York Heart Association class.
No significant improvement in left ventricular ejection fraction or dimensions was observed.
Adverse events like hypotension and hyperkalemia were comparable between groups.
Vericiguat's benefits were consistent across all prespecified subgroups.
The study suggests vericiguat as a potential treatment post-acute HF phase.

Hasty Briefsbeta